Evidence map›Paper›PMID 36631272›Full record

Trial reportNeurology2023

Prospective Long-term Follow-up of Focused Ultrasound Unilateral Subthalamotomy for Parkinson Disease.

Raúl Martínez-Fernández, Elena Natera-Villalba, Jorge U Máñez Miró, Rafael Rodriguez-Rojas, Marta Marta Del Álamo, José Ángel Pineda-Pardo, Claudia Ammann, Ignacio Obeso, David Mata-Marín, Frida Hernández-Fernández and 4 more

Registry-linked trialOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02912871 (A Pilot Clinical Trial of the Feasibility, Safety and Efficacy of Subthalamotomy Using the ExAblate Transcranial System to Treat the Cardinal Motor Features of Parkinson's Disease), which is not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
9.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02912871 nacompletednot on this map

A Pilot Clinical Trial of the Feasibility, Safety and Efficacy of Subthalamotomy Using the ExAblate Transcranial System to Treat the Cardinal Motor Features of Parkinson's Disease

TypeinterventionalSponsorFundación de investigación HMRan2016 to 2017Enrolled10ConditionsParkinson's DiseaseArmsMRIgHIFU unilateral subthalamotomy
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Review
  6. Article
  7. Advanced Therapeutics in Parkinson's Disease: What's New?Current neurology and neuroscience reports · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Raúl Martínez-FernándezFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain.ORCID 0000-0002-0305-013X
Elena Natera-VillalbaFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain.ORCID 0000-0001-5771-5005
Jorge U Máñez MiróFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain.ORCID 0000-0002-8995-8340
Rafael Rodriguez-RojasFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain.ORCID 0000-0002-2903-199X
Marta Marta Del ÁlamoFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain.
José Ángel Pineda-PardoFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain.ORCID 0000-0002-8776-0031
Claudia AmmannFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain.ORCID 0000-0002-4717-8573
Ignacio ObesoFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain. jobeso.hmcinac@hmhospitales.com.ORCID 0000-0001-8783-7281
David Mata-MarínFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain.ORCID 0000-0003-1447-3872
Frida Hernández-FernándezFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain.
Carmen Gasca-SalasFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain.ORCID 0000-0001-7411-8106
Michele MatarazzoFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain.ORCID 0000-0002-2907-8667
Fernando Alonso-FrechFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain.
Jose A ObesoFrom the HM CINAC (Centro Integral de Neurociencias Abarca Campal) (R.M.-F., E.N.-V., J.U.M.M., R.R.-R., M.D.A., J.A.P.-P., C.A., I.O., D.M.-M., F.H.-F., C.G.-S., M.M., F.A.-F., J.A.O.). Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid; CIBERNED (R.M.-F., R.R.-R., J.A.P.-P., I.O., C.G.-S., J.A.O.), Instituto Carlos III, Madrid; San Pablo-CEU University Medical School (R.M.-F., J.A.O.), Madrid, Spain. J.U.M.M. is currently at the Department of Neurology, IMED Hospitales, Valencia and the Universidad Autónoma de Madrid University-Instituto Cajal, Madrid, Spain. jobeso.hmcinac@hmhospitales.com.ORCID 0000-0002-6996-8613
Instituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesUnilateral magnetic resonance-guided focused ultrasound subthalamotomy (FUS-STN) has been shown to improve the cardinal motor features of Parkinson disease (PD). Whether this effect is sustained is not known. This study aims to report the long-term outcome of patients with PD treated with unilateral FUS-STN.

methodsWe conducted a prospective open-label study of patients with asymmetrical PD who underwent unilateral FUS-STN. All patients were evaluated up to 36 months after treatment. The primary outcome was the difference from baseline to 36 months after FUS-STN in the score of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor part (III) for the treated hemibody in the off-medication state. The safety outcome included all adverse events occurring during follow-up. Secondary outcomes were the change in the MDS-UPDRS III score on-medication; subscores of rigidity, bradykinesia, tremor, and axial features; total MDS-UPDRS III; and the MDS-UPDRS part IV. Functional disability and quality of life were assessed using the MDS-UPDRS II and the PDQ39, respectively. Patient impression of change and satisfaction with the treatment were self-assessed. The Wilcoxon signed-rank test with subsequent Bonferroni's correction was used for data analysis.

resultsThirty-two patients with PD were evaluated at 36 months after treatment. The mean (±SD) age at baseline was 56.0 ± 10.1 years, with a mean disease duration of 6.8 ± 2.8 years. The MDS-UPDRS III score for the treated hemibody off-medication was improved by 52.3% from baseline to 3 years (score reduction from 19.0 ± 3.2 to 8.9 ± 3.3, 95% CI 8.7 to 11.6, DISCUSSION: The benefit of unilateral FUS-STN on PD motor features is sustained in the long term. FUS-STN contributes to better clinical control over several years of evolution. NCT02912871/03454425. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence on the utility of focused ultrasound unilateral subthalamotomy in the treatment of people with Parkinson disease.

Indexed as

Deep Brain StimulationParkinson DiseaseSubthalamic NucleusAgedFollow-Up StudiesHumansMiddle AgedProspective StudiesQuality of LifeTreatment Outcome

Identifiers

PMID36631272
PMCPMC10065206
OpenAlexW4315606157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.